Clinical Efficacy of Combination of Late Course Accelerated Hyperfrationation Radiotherapy with Chemotherapy in Treating Esophageal Carcinoma

Objective To compare the clinical efficacy of late course accelerated hyperfractionation radiotherapy plus chemotherapy(LCAHR+C) and late course accelerated hyper fractionation radiotherapy(LCAHR).Methods 36 patients with mid-upper segment esophageal carcinoma were randomly divided into two groups:(1) LCAFR group:18 patients received 2 Gy per day,5 times a week,till DT 40 Gy.Then traditional radiotherapy was applied and kept away with vertebral canal,1.2 Gy per fraction,2 times per day(interval of six hours),to a total dose of 65 Gy.(2) LCAHR+C group: 18 patients received the same radiotherapy as LCAHR,supplemented with concurrent chemotherapy.The chemotherapy scheme was consecutive intravenous infusion of cisplatin(DDP) 40mg/d for days1 ～3 and consecutively pumping of 5-fluorouracil(5-Fu) 3g for 5 days.It was given 2 cycles.Results The survival rate of 1-year and 3-year in LCAFR+C group and in LCAFR group was 83.3%,77.7% and 38.9%,33.4% respectively.There was no significant difference between two groups(P0.05).The local control rate of 1-year and 3-year in LCAFR+C group and in LCAFR group was 88.9%,72.2% and 61.1%,38.9% respectively.There was no significant difference between two groups(P 0.05).Conclusion LCAHR plus concurrent chemotherapy can not significantly improve the survival rate of patients with esophageal cancer but has a tendency to improve the local control rate of esophageal cancer.